$2.15 Billion is the total value of Cormorant Asset Management, LP's 73 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 56.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $257,750,000 | – | 1,000,000 | +100.0% | 11.98% | – |
| PRNB | Buy | PRINCIPIA BIOPHARMA INC | $124,698,000 | +14.3% | 2,100,000 | +5.5% | 5.79% | +33.1% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $85,550,000 | -2.9% | 2,950,000 | +17.4% | 3.98% | +13.1% |
| XLRN | New | ACCELERON PHARMA INC | $74,143,000 | – | 825,000 | +100.0% | 3.44% | – |
| VIE | Buy | VIELA BIO INC | $66,975,000 | +64.7% | 1,762,500 | +17.7% | 3.11% | +91.9% |
| RVMD | New | REVOLUTION MEDICINES INC | $60,627,000 | – | 2,767,078 | +100.0% | 2.82% | – |
| EIDX | Buy | EIDOS THERAPEUTICS INC | $53,889,000 | +89.4% | 1,100,000 | +121.9% | 2.50% | +120.6% |
| YMAB | Buy | Y-MABS THERAPEUTICS INC | $45,210,000 | -9.7% | 1,732,200 | +8.1% | 2.10% | +5.2% |
| ASND | Buy | ASCENDIS PHARMA A Scall | $39,414,000 | +13.3% | 350,000 | +40.0% | 1.83% | +31.9% |
| OMER | Buy | OMEROS CORP | $33,742,000 | +57.0% | 2,523,700 | +65.5% | 1.57% | +83.0% |
| AGEN | New | AGENUS INC | $29,827,000 | – | 12,174,486 | +100.0% | 1.39% | – |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $26,316,000 | -4.8% | 450,000 | +30.4% | 1.22% | +10.9% |
| CCXI | Buy | CHEMOCENTRYX INCcall | $25,113,000 | +154.0% | 625,000 | +150.0% | 1.17% | +195.4% |
| IGMS | Buy | IGM BIOSCIENCES INC | $23,926,000 | +300.9% | 426,104 | +172.4% | 1.11% | +367.2% |
| MYOV | Buy | MYOVANT SCIENCES LTD | $19,630,000 | -36.8% | 2,600,000 | +30.0% | 0.91% | -26.4% |
| ANAB | Buy | ANAPTYSBIO INC | $15,655,000 | +164.0% | 1,107,900 | +203.5% | 0.73% | +206.8% |
| ZLAB | Buy | ZAI LAB LTDadr | $14,882,000 | +29.1% | 289,092 | +4.3% | 0.69% | +50.2% |
| BEAM | New | BEAM THERAPEUTICS INC | $14,336,000 | – | 796,429 | +100.0% | 0.67% | – |
| FIXX | New | HOMOLOGY MEDICINES INC | $9,324,000 | – | 600,000 | +100.0% | 0.43% | – |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $9,200,000 | -32.0% | 5,000,000 | +25.0% | 0.43% | -20.9% |
| INSM | New | INSMED INC | $5,807,000 | – | 362,273 | +100.0% | 0.27% | – |
| ARCT | New | ARCTURUS THERAPEUTICS HLDG I | $3,561,000 | – | 262,037 | +100.0% | 0.16% | – |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $3,416,000 | +26.3% | 341,618 | +35.2% | 0.16% | +47.2% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $2,311,000 | +78.5% | 100,000 | +100.0% | 0.11% | +105.8% |
| FATE | New | FATE THERAPEUTICS INC | $1,666,000 | – | 75,000 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.